StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Corporate ActionApr 29, 2026, 04:34 PM

BCAB Effects 50-for-1 Share Consolidation; Amends 2025 10-K

AI Summary

BioAtla, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include previously omitted Part III information covering corporate governance, executive compensation, and related matters. Additionally, the company announced a 50-for-1 share consolidation of its common stock, effective April 6, 2026, with all share and per share amounts retroactively adjusted in the amendment. New certifications from the principal executive and financial officers were also filed.

Key Highlights

  • BioAtla effected a 50-for-1 share consolidation on April 6, 2026.
  • All share and per share amounts in the amendment are retroactively adjusted.
  • Filed Amendment No. 1 to the 2025 Form 10-K to include omitted Part III information.
  • Part III details Directors, Executive Officers, Corporate Governance, and Executive Compensation.
  • New certifications from principal executive and financial officers were filed.
  • Christian Vasquez was appointed Chief Financial Officer in 2026.
  • The Board of Directors consists of 7 members, including 3 identified as female.